Literature DB >> 25106082

Hemostatic efficacy of a novel, PEG-coated collagen pad in clinically relevant animal models.

Kevin M Lewis1, Alexandra Schiviz2, Hans-Christian Hedrich2, Johannes Regenbogen2, Andreas Goppelt2.   

Abstract

PURPOSE: Currently available hemostatic pads are effective in treating oozing bleeds, but otherwise ineffective in more severe bleeding. This study investigates the hemostatic efficacy of a new hemostatic pad with advanced sealing properties using protein-reactive polyethylene glycol-coated collagen (PCC, Hemopatch) versus an oxidized regenerated cellulose (ORC, Tabotamp/Surgicel Original) in a leporine arterial bleeding model of vascular reconstruction and a porcine hepatic model of general surgery.
METHODS: In both models, paired lesions were created and treated according to a randomized scheme and evaluated up to 10 min after application (40 lesions/group/model). Arterial needle holes were created in the femoral arteries of anesthetized rabbits and hepatic lesions were created into hepatic parenchyma of anesthetized pigs. Both models were heparinized to mimic clinical comorbidity.
RESULTS: In the leporine vascular surgical model, PCC provided superior hemostatic success compared to ORC at 2 min (Odds Ratio of Success: 85, 95% CI: 25.8-282) and similar hemostatic success at 10 min. In the porcine hepatic model, PCC provided superior hemostatic success compared to ORC at 2 (98 vs 55%, P < 0.001), 3 (93 vs 65%, P < 0.001), 4 (98 vs 68%, P < 0.001) and 5 min (95 vs 80%, P < 0.001), but similar hemostatic success at 8 and 10 min. DISCUSSION: PCC provided 75.4% greater hemostatic success at 2 min in the arterial model and was at least 100 times more likely to be hemostat effective at 2 min in the hepatic model than ORC.
CONCLUSIONS: PCC provided faster hemostasis than ORC in a vascular and hepatic surgical model with impaired coagulation.
Copyright © 2014 Baxter International, Inc. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Evarrest; Hemopatch; Hemostasis; Hepatic hemostasis; Surgicel; Tabotamp; Vascular hemostasis; Veriset

Mesh:

Substances:

Year:  2014        PMID: 25106082     DOI: 10.1016/j.ijsu.2014.07.017

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  6 in total

1.  Next Generation Hemostatic Materials Based on NHS-Ester Functionalized Poly(2-oxazoline)s.

Authors:  Marcel A Boerman; Edwin Roozen; María José Sánchez-Fernández; Abraham R Keereweer; Rosa P Félix Lanao; Johan C M E Bender; Richard Hoogenboom; Sander C Leeuwenburgh; John A Jansen; Harry Van Goor; Jan C M Van Hest
Journal:  Biomacromolecules       Date:  2017-07-25       Impact factor: 6.988

2.  Case Report of a Novel Technique for Repair of the Vertebral Artery During Cranial Surgery.

Authors:  Manjunath Prasad; Nitin Mukerji
Journal:  Neurol Ther       Date:  2019-07-05

3.  Hemopatch® as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation.

Authors:  Marie C Hupe; Maximilian Büttner; Pouriya Faraj Tabrizi; Axel S Merseburger; Markus A Kuczyk; Florian Imkamp
Journal:  Adv Ther       Date:  2020-12-04       Impact factor: 3.845

Review 4.  Control of bleeding in surgical procedures: critical appraisal of HEMOPATCH (Sealing Hemostat).

Authors:  Kevin Michael Lewis; Carl Erik Kuntze; Heinz Gulle
Journal:  Med Devices (Auckl)       Date:  2015-12-22

5.  Improved bleeding scores using Gelfoam(®) Powder with incremental concentrations of bovine thrombin in a swine liver lesion model.

Authors:  Dennis C Morse; Elif Silva; Jolee Bartrom; Kelli Young; Eric J Bass; David Potter; Trevor Bieber
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

6.  Versatility and clinical effectiveness of a synthetic sealing hemostatic patch as alternative to parenchyma suturing in laparoscopic partial nephrectomy.

Authors:  Eva Erne; Stephan Kruck; Tilman Todenhoefer; Stefan Aufderklamm; Bastian Amend; Jens Bedke; Arnulf Stenzl; Steffen Rausch
Journal:  Surg Endosc       Date:  2021-02-16       Impact factor: 4.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.